Navigation Links
BioCryst to Present at Oppenheimer Healthcare Conference
Date:10/29/2009

BIRMINGHAM, Ala., Oct. 29 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, and Stuart Grant, Chief Financial Officer of BioCryst, plan to provide a corporate summary at the Oppenheimer & Co., Inc. 20th Annual Healthcare Conference in New York on Wednesday, November 4, 2009 at 1:35 p.m. Eastern Time.

Links to a live audio Web cast and replay of the presentation may be accessed on the BioCryst Web site at www.biocryst.com.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

    BCRXW

    SOURCE BioCryst Pharmaceuticals, Inc.


    '/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Emergency Use Authorization Granted For BioCrysts Peramivir
2. BioCryst to Present at JMP Securities Healthcare Conference
3. BioCryst Clarifies Government Declaration Regarding Peramivir
4. BioCryst Provides Update Regarding Peramivir for Influenza
5. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
6. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
7. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
8. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
9. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
10. BioCryst Updates Peramivir Clinical Development Plan
11. BioCryst Provides Forodesine HCl Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... manufacturing solutions for cell and advanced therapies , ... the French biopharmaceutical company developing "tumor starvation" treatments ... unmet medical needs. Under the agreement, Invetech will ... products based on Erytech,s proprietary ERYCAPS technology platform, ...
(Date:1/18/2017)... January 18, 2017 After the recent ... the use of cannabis both for medical and recreational purposes ... Americans open to the use of cannabis, but the focus ... to Arcview Market Research, the North American legal cannabis market ... the previous year. The research projects sales will grow at ...
(Date:1/17/2017)... 2017 North America Insulin Delivery Market Outlook ... America Insulin Delivery Market Outlook to 2022", provides key ... The report provides value, in millions of US dollars, ... segments - Insulin Pens, Insulin Pumps, Insulin Syringes and ... company shares and distribution shares data for each of ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their ... that they have achieved certification to ISO 13485. This certification is another way they ... to date products and services that they need. , The ISO 13485 Certification is ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Hear the ... project with the donation of cochlear implants. In February 2017, the first three ... a fair chance of leading an independent life. This engagement builds on the ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... January is National Stalking Awareness Month ... choose to lurk in the corners and commit the crime of stalking, a very real ... and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know it. ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks from ... campaigns regarding the topic of Beauty and Personal Care. , Everyone ... better way to commit to these changes than beginning with personal care and beauty ...
Breaking Medicine News(10 mins):